$ADRX · ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. closed its initial public offering on September 28, 2026, selling 26,250,000 shares of common stock at $17.00 per share for aggregate gross proceeds of approximately $446.3 million. Concurrently, AbbVie Inc. purchased 5,255,542 shares in a private placement at the same $17.00 price, contributing approximately $89.3 million in gross proceeds and resulting in AbbVie owning approximately 4.9% of outstanding shares post-IPO. Total gross proceeds across both transactions were approximately $535.6 million before underwriting discounts, placement agent fees, and offering/
- IPO of 26,250,000 shares at $17.00 per share raised ~$446.3M in gross proceeds.
- AbbVie purchased 5,255,542 shares in a concurrent private placement for ~$89.3M, taking a ~4.9% stake.
- Total aggregate gross proceeds from IPO and private placement were approximately $535.6M.
- Placement agents received a 2.0% fee on the AbbVie private placement.
- Company filed amended and restated certificate of incorporation and bylaws effective upon IPO closing.
Price data unavailable.
A biotech IPO with a top-tier pharma strategic investor (AbbVie) buying in at the IPO price is a strong endorsement signal rarely seen in the current market.
Biotech IPOs with strategic pharma anchor investments signal validation; AbbVie's concurrent $89.3M commitment at the IPO price mirrors the structure seen in other high-conviction biotech debuts where a large pharma partner takes a minority stake alongside the public listing.
Shares sold to AbbVie are unregistered and restricted under Section 4(a)(2) of the Securities Act, limiting immediate resale but creating potential overhang if AbbVie eventually liquidates its ~4.9% position.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.